Fintel reports that on January 10, 2025, Needham initiated coverage of Evolent Health (NYSE:EVH) with a Buy recommendation.
RBC Capital analyst Sean Dodge maintained a Buy rating on Evolent Health (EVH – Research Report) yesterday and set a price target of $17.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback